$REGN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in REGENERON PHARMACEUTICALS, INC.. Get notifications about new insider transactions in REGENERON PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 4 5 6 7 8 9 10 11 12 ... 48 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 458.59 | 460 | 210,951 | 13,446 | 13.9 K to 13.4 K (-3.31 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 457.27 | 141 | 64,475 | 13,906 | 14 K to 13.9 K (-1.00 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 456.63 | 743 | 339,276 | 14,047 | 14.8 K to 14 K (-5.02 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 455.56 | 2,967 | 1,351,647 | 14,790 | 17.8 K to 14.8 K (-16.71 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 454.58 | 102 | 46,367 | 17,757 | 17.9 K to 17.8 K (-0.57 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 453.45 | 113 | 51,240 | 17,859 | 18 K to 17.9 K (-0.63 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 452.08 | 130 | 58,770 | 17,972 | 18.1 K to 18 K (-0.72 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 451.47 | 233 | 105,193 | 18,102 | 18.3 K to 18.1 K (-1.27 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 450.10 | 125 | 56,263 | 18,335 | 18.5 K to 18.3 K (-0.68 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 449.53 | 236 | 106,089 | 18,460 | 18.7 K to 18.5 K (-1.26 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 448.86 | 240 | 107,726 | 18,696 | 18.9 K to 18.7 K (-1.27 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 445.91 | 120 | 53,509 | 18,936 | 19.1 K to 18.9 K (-0.63 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 444.65 | 490 | 217,879 | 19,056 | 19.5 K to 19.1 K (-2.51 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 443.67 | 264 | 117,129 | 19,546 | 19.8 K to 19.5 K (-1.33 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 440.24 | 395 | 173,895 | 19,810 | 20.2 K to 19.8 K (-1.95 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 439.73 | 231 | 101,578 | 20,205 | 20.4 K to 20.2 K (-1.13 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 438.63 | 256 | 112,289 | 20,436 | 20.7 K to 20.4 K (-1.24 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 437.41 | 480 | 209,957 | 20,692 | 21.2 K to 20.7 K (-2.27 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 436.43 | 348 | 151,878 | 21,172 | 21.5 K to 21.2 K (-1.62 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 435.93 | 209 | 91,109 | 21,520 | 21.7 K to 21.5 K (-0.96 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Payment of Exercise | F | 451.89 | 14,651 | 6,620,640 | 21,729 | 36.4 K to 21.7 K (-40.27 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Buy | M | 52.03 | 25,000 | 1,300,750 | 36,380 | 11.4 K to 36.4 K (+219.68 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Option Exercise | M | 33.42 | 2,500 | 83,550 | 12,500 | |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 455.00 | 500 | 227,500 | 9,000 | 9.5 K to 9 K (-5.26 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 450.00 | 500 | 225,000 | 9,500 | 10 K to 9.5 K (-5.00 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 457.00 | 400 | 182,800 | 3,700 | 4.1 K to 3.7 K (-9.76 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 450.00 | 400 | 180,000 | 4,100 | 4.5 K to 4.1 K (-8.89 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 455.00 | 300 | 136,500 | 2,400 | 2.7 K to 2.4 K (-11.11 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 450.00 | 300 | 135,000 | 2,700 | 3 K to 2.7 K (-10.00 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 460.00 | 2,500 | 1,150,000 | 115,415 | 117.9 K to 115.4 K (-2.12 %) |
Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Buy | M | 33.42 | 2,500 | 83,550 | 117,915 | 115.4 K to 117.9 K (+2.17 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,000 | 272,700 | 54,500 | |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,000 | 272,700 | 55,500 | |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 460.05 | 34 | 15,642 | 24,973 | 25 K to 25 K (-0.14 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 458.35 | 27 | 12,375 | 25,007 | 25 K to 25 K (-0.11 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 457.23 | 25 | 11,431 | 25,034 | 25.1 K to 25 K (-0.10 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 456.67 | 10 | 4,567 | 25,059 | 25.1 K to 25.1 K (-0.04 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 455.37 | 32 | 14,572 | 25,069 | 25.1 K to 25.1 K (-0.13 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 454.85 | 18 | 8,187 | 25,101 | 25.1 K to 25.1 K (-0.07 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 453.36 | 44 | 19,948 | 25,119 | 25.2 K to 25.1 K (-0.17 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 452.04 | 10 | 4,520 | 25,163 | 25.2 K to 25.2 K (-0.04 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 455.13 | 17 | 7,737 | 25,173 | 25.2 K to 25.2 K (-0.07 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 454.67 | 4 | 1,819 | 25,190 | 25.2 K to 25.2 K (-0.02 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 453.60 | 16 | 7,258 | 25,194 | 25.2 K to 25.2 K (-0.06 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 450.80 | 35 | 15,778 | 25,210 | 25.2 K to 25.2 K (-0.14 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 449.50 | 54 | 24,273 | 25,245 | 25.3 K to 25.2 K (-0.21 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 448.54 | 18 | 8,074 | 25,299 | 25.3 K to 25.3 K (-0.07 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 447.11 | 37 | 16,543 | 25,317 | 25.4 K to 25.3 K (-0.15 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 445.35 | 11 | 4,899 | 25,354 | 25.4 K to 25.4 K (-0.04 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 444.03 | 12 | 5,328 | 25,365 | 25.4 K to 25.4 K (-0.05 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 438.00 | 10 | 4,380 | 25,377 | 25.4 K to 25.4 K (-0.04 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 447.30 | 800 | 357,840 | 25,387 | 26.2 K to 25.4 K (-3.05 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,000 | 272,700 | 26,187 | 25.2 K to 26.2 K (+3.97 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 406.59 | 786 | 319,580 | 25,187 | 26 K to 25.2 K (-3.03 %) |
Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,000 | 272,700 | 25,973 | 25 K to 26 K (+4.00 %) |
Feb 25 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 273.67 | 2,000 | 547,340 | 250 | |
Feb 25 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 419.03 | 44 | 18,437 | 643 | 687 to 643 (-6.40 %) |
Feb 25 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 419.00 | 1,956 | 819,564 | 687 | 2.6 K to 687 (-74.01 %) |
Feb 25 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 273.67 | 2,000 | 547,340 | 2,643 | 643 to 2.6 K (+311.04 %) |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 500 | 136,350 | 56,500 | |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 407.66 | 5 | 2,038 | 24,973 | 25 K to 25 K (-0.02 %) |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 402.30 | 4 | 1,609 | 24,978 | 25 K to 25 K (-0.02 %) |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 401.70 | 8 | 3,214 | 24,982 | 25 K to 25 K (-0.03 %) |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 400.54 | 21 | 8,411 | 24,990 | 25 K to 25 K (-0.08 %) |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 399.89 | 22 | 8,798 | 25,011 | 25 K to 25 K (-0.09 %) |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 398.63 | 47 | 18,736 | 25,033 | 25.1 K to 25 K (-0.19 %) |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 402.34 | 393 | 158,120 | 25,080 | 25.5 K to 25.1 K (-1.54 %) |
Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 500 | 136,350 | 25,473 | 25 K to 25.5 K (+2.00 %) |
Feb 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 382.83 | 1,000 | 382,830 | 9,643 | 10.6 K to 9.6 K (-9.40 %) |
Jan 28 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 343.02 | 214 | 73,406 | 49,951 | 50.2 K to 50 K (-0.43 %) |
Jan 28 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 342.44 | 1,399 | 479,074 | 50,165 | 51.6 K to 50.2 K (-2.71 %) |
Jan 28 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 341.58 | 3,283 | 1,121,407 | 51,564 | 54.8 K to 51.6 K (-5.99 %) |
Jan 28 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 340.56 | 1,355 | 461,459 | 54,847 | 56.2 K to 54.8 K (-2.41 %) |
Jan 28 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 339.37 | 567 | 192,423 | 56,202 | 56.8 K to 56.2 K (-1.00 %) |
Jan 28 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 338.54 | 712 | 241,040 | 56,769 | 57.5 K to 56.8 K (-1.24 %) |
Jan 28 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 337.46 | 270 | 91,114 | 57,481 | 57.8 K to 57.5 K (-0.47 %) |
Jan 28 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Sell | S | 336.78 | 200 | 67,356 | 57,751 | 58 K to 57.8 K (-0.35 %) |
Jan 27 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | M | 30.63 | 500 | 15,315 | 3,380 | |
Jan 27 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Buy | M | 30.63 | 500 | 15,315 | 13,097 | 12.6 K to 13.1 K (+3.97 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Grant | A | 0.00 | 320 | 0 | 1,830 | 1.5 K to 1.8 K (+21.19 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Grant | A | 0.00 | 320 | 0 | 643 | 323 to 643 (+99.07 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Grant | A | 0.00 | 320 | 0 | 643 | 323 to 643 (+99.07 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Grant | A | 0.00 | 320 | 0 | 10,643 | 10.3 K to 10.6 K (+3.10 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Grant | A | 0.00 | 320 | 0 | 29,143 | 28.8 K to 29.1 K (+1.11 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | Bassler Bonnie L | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | Bassler Bonnie L | Director | Grant | A | 0.00 | 320 | 0 | 643 | 323 to 643 (+99.07 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Option Exercise | M | 24.41 | 15,000 | 366,150 | 0 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Grant | A | 0.00 | 320 | 0 | 115,415 | 115.1 K to 115.4 K (+0.28 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 371.98 | 15,000 | 5,579,700 | 115,095 | 130.1 K to 115.1 K (-11.53 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Buy | M | 24.41 | 15,000 | 366,150 | 130,095 | 115.1 K to 130.1 K (+13.03 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | COLES N ANTHONY | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | COLES N ANTHONY | Director | Grant | A | 0.00 | 320 | 0 | 643 | 323 to 643 (+99.07 %) |
Dec 23 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | M | 30.63 | 400 | 12,252 | 3,880 | |
Dec 23 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Buy | M | 30.63 | 400 | 12,252 | 12,597 | 12.2 K to 12.6 K (+3.28 %) |
Dec 18 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | I | 375.31 | 126 | 47,289 | 2,200 | 2.3 K to 2.2 K (-5.42 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | A | 372.46 | 6,120 | 2,279,455 | 6,120 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | M | 52.03 | 3,100 | 161,293 | 7,226 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 378.27 | 51 | 19,292 | 12,197 | 12.2 K to 12.2 K (-0.42 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 377.38 | 346 | 130,573 | 12,248 | 12.6 K to 12.2 K (-2.75 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 376.27 | 470 | 176,847 | 12,594 | 13.1 K to 12.6 K (-3.60 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 375.58 | 624 | 234,362 | 13,064 | 13.7 K to 13.1 K (-4.56 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Sell | S | 374.82 | 191 | 71,591 | 13,688 | 13.9 K to 13.7 K (-1.38 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Payment of Exercise | F | 377.16 | 1,418 | 534,813 | 13,879 | 15.3 K to 13.9 K (-9.27 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Buy | M | 52.03 | 3,100 | 161,293 | 15,297 | 12.2 K to 15.3 K (+25.42 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Grant | A | 0.00 | 2,500 | 0 | 12,197 | 9.7 K to 12.2 K (+25.78 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Grant | A | 0.00 | 1,020 | 0 | 9,697 | 8.7 K to 9.7 K (+11.76 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Option Exercise | A | 0.00 | 9,086 | 0 | 9,086 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Option Exercise | A | 372.46 | 29,177 | 10,867,265 | 29,177 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Option Exercise | M | 21.25 | 107,655 | 2,287,669 | 0 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 379.14 | 33 | 12,512 | 304,485 | 304.5 K to 304.5 K (-0.01 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 378.38 | 3,602 | 1,362,925 | 304,518 | 308.1 K to 304.5 K (-1.17 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 377.47 | 5,732 | 2,163,658 | 308,120 | 313.9 K to 308.1 K (-1.83 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 376.36 | 13,060 | 4,915,262 | 313,852 | 326.9 K to 313.9 K (-3.99 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 375.55 | 21,910 | 8,228,301 | 326,912 | 348.8 K to 326.9 K (-6.28 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 374.79 | 6,873 | 2,575,932 | 348,822 | 355.7 K to 348.8 K (-1.93 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 373.26 | 632 | 235,900 | 355,695 | 356.3 K to 355.7 K (-0.18 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Payment of Exercise | F | 377.16 | 55,813 | 21,050,431 | 356,327 | 412.1 K to 356.3 K (-13.54 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Buy | M | 21.25 | 107,655 | 2,287,669 | 412,140 | 304.5 K to 412.1 K (+35.36 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Option Exercise | A | 0.00 | 25,155 | 0 | 25,155 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Option Exercise | A | 372.46 | 81,278 | 30,272,804 | 81,278 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Option Exercise | M | 21.25 | 150,000 | 3,187,500 | 0 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Option Exercise | M | 21.25 | 95,295 | 2,025,019 | 150,000 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Option Exercise | G | 0.00 | 23,367 | 0 | 0 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Option Exercise | G | 0.00 | 23,367 | 0 | 23,367 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 325,986 | 0 | 0 | 326 K to 0 (-100.00 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 2,366 | 0 | 325,989 | 328.4 K to 326 K (-0.72 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 75,036 | 0 | 328,352 | 253.3 K to 328.4 K (+29.62 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 500,000 | 0 | 253,316 | 753.3 K to 253.3 K (-66.37 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 150,722 | 0 | 753,316 | 602.6 K to 753.3 K (+25.01 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 500,000 | 0 | 500,000 | 0 to 500 K |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 150,722 | 0 | 249,278 | 400 K to 249.3 K (-37.68 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 75,036 | 0 | 0 | 75 K to 0 (-100.00 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Payment of Exercise | F | 377.16 | 77,767 | 29,330,602 | 444,109 | 521.9 K to 444.1 K (-14.90 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Buy | M | 21.25 | 150,000 | 3,187,500 | 521,876 | 371.9 K to 521.9 K (+40.34 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Payment of Exercise | F | 377.16 | 49,405 | 18,633,590 | 371,876 | 421.3 K to 371.9 K (-11.73 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Buy | M | 21.25 | 95,295 | 2,025,019 | 421,281 | 326 K to 421.3 K (+29.23 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President and CSO | Gift | G | 0.00 | 325,986 | 0 | 325,986 | 0 to 326 K |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Option Exercise | A | 372.46 | 24,500 | 9,125,270 | 24,500 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Grant | A | 0.00 | 10,000 | 0 | 57,951 | 48 K to 58 K (+20.85 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Grant | A | 0.00 | 2,625 | 0 | 47,951 | 45.3 K to 48 K (+5.79 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | A | 372.46 | 24,500 | 9,125,270 | 24,500 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Grant | A | 0.00 | 2,625 | 0 | 14,438 | 11.8 K to 14.4 K (+22.22 %) |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 273.67 | 4,000 | 1,094,680 | 2,250 | |
Dec 13 2019 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 374.86 | 1,585 | 594,153 | 323 | 1.9 K to 323 (-83.07 %) |